GE gets FDA priority review for imaging agent
Thursday, June 12, 2008 - 14:14
in Health & Medicine
CHICAGO (Reuters) - GE Healthcare, a unit of General Electric Corp, said on Thursday U.S. health regulators granted it priority review on its application for AdreView, a molecular imaging agent for the detection of neuroendocrine tumors in children and adult patients.